Compare Adaptive Biotechnologies Corp (ADPT) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs abrdn Physical Palladium Shares ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while abrdn Physical Palladium Shares ETF trades at $24.71. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | PALL | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $25.45 | $37.18 |
52-Week Low | $12.30 | $19.96 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
PALL trades at $24.85, down 1.04% over 24 hours. Technical indicators show a bullish trend with moving averages supporting a buy signal, though the RSI suggests potential overbought conditions. The stock underwent a 1:5 split effective May 18, 2026. Recent financial ratios are unavailable, limiting fundamental assessment. News sentiment highlights palladium's price weakness as a potential buying opportunity amid supply risks and industrial demand.
Outlook: PALL presents a speculative opportunity tied to palladium's recovery, with technical strength but limited fundamental data. Risks include commodity price volatility and macroeconomic factors. Investors should weigh the bullish technicals against the absence of current financial metrics and exposure to precious metal market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
